Publicaciones en colaboración con investigadores/as de Complexo Hospitalario Universitario de Ferrol (14)

2020

  1. Fracture risk assessment in the general population in Spain by FRAX® algorithm. EPISER2016 study

    Medicina Clinica, Vol. 154, Núm. 5, pp. 163-170

2019

  1. Diverse large HIV-1 non-subtype B clusters are spreading among men who have sex with men in Spain

    Frontiers in Microbiology, Vol. 10, Núm. APR

2017

  1. Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253

2015

  1. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial

    The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784

2012

  1. Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-for the treatment of chronic hepatitis C in HIV-infected patients: The PERICO trial

    Journal of Infectious Diseases, Vol. 206, Núm. 6, pp. 961-968

  2. Rapid expansion of a HIV-1 subtype f cluster of recent origin among men who have sex with men in Galicia Spain

    Journal of Acquired Immune Deficiency Syndromes

2008

  1. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of hiv type 1 infection: Final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903

    Clinical Infectious Diseases, Vol. 47, Núm. 8, pp. 1083-1092

  2. Low rate of adverse hepatic events associated with fosamprenavir/ritonavir-based antiretroviral regimens

    HIV Clinical Trials, Vol. 9, Núm. 5, pp. 309-313

2007

  1. Impacto de la reducción de dosis de estavudina en su perfil de eficacia/seguridad en pacientes con infección por el virus de la inmunodeficiencia humana inmunológica y virológicamente estables

    Medicina Clinica, Vol. 129, Núm. 10, pp. 361-365

2006

  1. "Liver toxicity and metabolic alterations associated with nevirapine therapy and the influence of hepatitis C virus infection"

    Nutrition and Metabolic Disorders in HIV Infection, Vol. 5, Núm. 1, pp. 891-897

  2. Actividad asistencial en las consultas externas de las unidades de reumatología de Galicia

    Reumatologia Clinica, Vol. 2, Núm. 5, pp. 239-246

1997

  1. A pilot study on the efficacy of escalating dosage of alpha-interferon for chronic hepatitis C in HIV-infected patients

    Journal of Infection, Vol. 35, Núm. 3, pp. 225-230

  2. Multicenter randomized, controlled study of intramuscular administration of interferon-β for the treatment of chronic hepatitis C

    Journal of Interferon and Cytokine Research, Vol. 17, Núm. 1, pp. 27-30

  3. Tolerance and efficacy of subcutaneous interferon-β administered for treatment of chronic hepatitis C

    Journal of Interferon and Cytokine Research, Vol. 17, Núm. 2, pp. 65-67